Isoliquiritin apioside

Isoliquiritin apioside significantly decreases PMA-induced increases in MMP9 activities and suppresses PMA-induced activation of MAPK and NF-κB. Isoliquiritin apioside auppresseses invasiveness and angiogenesis of cancer cells and endothelial cells[1].

Product Specifications

CAS Number

[120926-46-7]

UNSPSC

12352005

Hazard Statement

H315, H319

Target

MMP; NF-κB; p38 MAPK

Type

Natural Products

Related Pathways

MAPK/ERK Pathway; Metabolic Enzyme/Protease; NF-κB

Applications

Cancer-Kinase/protease

Field of Research

Cancer

Assay Protocol

https://www.medchemexpress.com/isoliquiritin-apioside.html

Purity

99.87

Solubility

DMSO : 25 mg/mL (ultrasonic)

Smiles

O=C(C1=C(C=C(O)C=C1)O)/C=C/C(C=C2)=CC=C2O[C@H](O[C@H](CO)[C@@H](O)[C@@H]3O)[C@]3([H])O[C@H]4[C@@H]([C@](CO)(O)CO4)O

Molecular Formula

C26H30O13

Molecular Weight

550.51

Precautions

H315, H319

References & Citations

[1]Kim A1, et al. Isoliquiritin Apioside Suppresses in vitro Invasiveness and Angiogenesis of Cancer Cells and Endothelial Cells.Front Pharmacol. 2018 Dec 10;9:1455.